Quantum-Si Incorporated, a company pioneering next-generation
semiconductor chip-based proteomics, announced today the
appointment of Michael Mina, M.D., Ph.D., Assistant Professor of
Epidemiology, Immunology, Infectious Diseases and Pathology at the
Harvard T.H. Chan School of Public Health and Harvard Medical
School, as Chief Medical Advisor for the company.
“As we create the next generation of protein sequencing and
proteomics to transform how we study and diagnose disease, moving
from the analog to the digital world and allowing a level of
sensitivity, precision and understanding never before possible, Dr.
Mina’s expertise will be invaluable in guiding Quantum-Si’s
application efforts, and especially as we apply our technology to
help our customers in the revolution occurring in immuno-oncology
and immunology-related diagnostics and therapeutics,” said Dr.
Jonathan Rothberg, Founder of Quantum-Si. “Next-generation DNA
sequencing transformed our understanding of cancer, and working
with Dr. Mina, I’m convinced next-generation protein sequencing
will have an equally profound impact on immunology.”
In this role, Dr. Mina will work closely with the executive and
scientific teams to steer R&D and clinical plans to position
Quantum-Si as a leader in a new generation of technologies to
better understand biology and treat and cure diseases, better,
faster and more accurately.
“I’m excited to work alongside the highly-talented and
experienced Quantum-Si team to help pioneer a whole new field of
measuring, reading out, and visualizing proteins at the single
molecule and even single amino acid level to better solve human
diseases and create a new generation of tools for scientists and
clinicians to help people at massive scale,” said Dr. Mina. “This
role allows me to translate my work in public health, immunology,
and medicine into action —especially knowing that we are on the
verge of another scientific and medical breakthrough by leveraging
semiconductor technologies to bring the field of proteomics into
the 21st century in ways we have only begun to imagine.”
Dr. Mina is a core member of Harvard T.H. Chan School of Public
Health’s Center for Communicable Disease Dynamics (CCDD), a
Professor in the Department of Epidemiology and the Department of
Immunology and Infectious Diseases as well as a Professor and
Associate Medical Director in Clinical Pathology at Brigham and
Women’s Hospital, Harvard Medical School. He earned his M.D. and
Ph.D. degrees from Emory University and completed his post-doctoral
work in infectious diseases at Princeton University and Harvard
Medical School.
About Quantum-Si
Founded by Dr. Jonathan Rothberg in 2013, Quantum-Si is focused
on revolutionizing the growing field of proteomics. The company’s
suite of technologies are powered by a first-of-its-kind
semiconductor chip designed to enable single-molecule
next-generation protein sequencing, and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing.
On February 18, 2021, Quantum-Si and HighCape Capital
Acquisition Corp. (Nasdaq: CAPA) (“HighCape”), a healthcare-focused
special purpose acquisition company sponsored by leading healthcare
growth-equity investment firm HighCape Capital LP, announced a
proposed business combination.
Important Information About the Proposed Business Combination
and Where to Find It
In connection with the proposed business combination between
HighCape and Quantum-Si (the “Business Combination”), HighCape has
filed with the Securities and Exchange Commission (the “SEC”) a
registration statement on Form S-4 (the “Registration Statement”),
which includes a preliminary proxy statement/prospectus and, as
amended, will include a definitive proxy statement/prospectus, and
certain other related documents, which will be both the proxy
statement to be distributed to holders of shares of HighCape’s
common stock in connection with HighCape’s solicitation of proxies
for the vote by HighCape’s stockholders with respect to the
Business Combination and other matters as may be described in the
Registration Statement, as well as the prospectus relating to the
offer and sale of the securities of HighCape to be issued in the
Business Combination. HighCape’s stockholders and other interested
persons are advised to read the preliminary proxy
statement/prospectus included in the Registration Statement and the
amendments thereto and the definitive proxy statement/prospectus,
when available, as well as other documents filed with the SEC in
connection with the Business Combination, as these materials will
contain important information about the parties to the Business
Combination Agreement and the Business Combination. After the
Registration Statement is declared effective, the definitive proxy
statement/prospectus and other relevant materials for the Business
Combination will be mailed to stockholders of HighCape as of a
record date to be established for voting on the Business
Combination and other matters as may be described in the
Registration Statement. Stockholders will also be able to obtain
copies of the preliminary proxy statement/prospectus, the
definitive proxy statement/prospectus, and other documents filed
with the SEC that will be incorporated by reference therein,
without charge, once available, at the SEC’s web site at
www.sec.gov, or by directing a request to: HighCape Capital
Acquisition Corp., 452 Fifth Avenue, 21st Floor, New York, NY
10018, Attention: Kevin Rakin, or to
info@HighCapeacquisition.com.
Participants in the Solicitation
HighCape and its directors and executive officers may be deemed
participants in the solicitation of proxies from HighCape’s
stockholders with respect to the Business Combination. A list of
the names of those directors and executive officers and a
description of their interests in HighCape is contained in the
Registration Statement for the Business Combination, and will be
available free of charge at the SEC’s web site at www.sec.gov, or
by directing a request to HighCape Capital Acquisition Corp., 452
Fifth Avenue, 21st Floor, New York, NY 10018, Attention: Kevin
Rakin, or to info@HighCapeacquisition.com. Additional information
regarding the interests of such participants is contained in the
Registration Statement.
Quantum-Si and its directors and executive officers may also be
deemed to be participants in the solicitation of proxies from the
stockholders of HighCape in connection with the Business
Combination. A list of the names of such directors and executive
officers and information regarding their interests in the Business
Combination is contained in the Registration Statement.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the United States
Private Securities Litigation Reform Act of 1995. Quantum Si’s
actual results may differ from its expectations, estimates, and
projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue,” and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation,
Quantum-Si’s expectations with respect to future performance,
development of products and services, potential regulatory
approvals, and anticipated financial impacts and other effects of
the Business Combination, the satisfaction of the closing
conditions to Business Combination, the timing of the completion of
the Business Combination, and the size and potential growth of
current or future markets for the combined company’s future
products and services. These forward-looking statements involve
significant risks and uncertainties that could cause the actual
results to differ materially from those discussed in the
forward-looking statements. Most of these factors are outside
HighCape’s and Quantum-Si’s control and are difficult to predict.
Factors that may cause such differences include, but are not
limited to: the occurrence of any event, change, or other
circumstances that could give rise to the termination of the
Business Combination Agreement; the outcome of any legal
proceedings that may be instituted against HighCape and Quantum-Si
following the announcement of the Business Combination Agreement
and the transactions contemplated therein; the inability to
complete the Business Combination, including due to failure to
obtain approval of the stockholders of HighCape and Quantum-Si,
certain regulatory approvals, or satisfy other conditions to
closing in the Business Combination Agreement; the occurrence of
any event, change, or other circumstance that could give rise to
the termination of the Business Combination Agreement or could
otherwise cause the transaction to fail to close; the impact of
COVID-19 on Quantum-Si’s business and/or the ability of the parties
to complete the Business Combination; the inability to obtain or
maintain the listing of the combined company’s shares of Class A
common stock on The Nasdaq Stock Market following the Business
Combination; the risk that the Business Combination disrupts
current plans and operations as a result of the announcement and
consummation of the Business Combination; the ability to recognize
the anticipated benefits of the Business Combination, which may be
affected by, among other things, competition and the ability of
Quantum-Si to grow and manage growth profitably and retain its key
employees; costs related to the Business Combination; changes in
applicable laws or regulations; the ability of the combined company
to raise financing in the future; the success, cost and timing of
Quantum-Si’s and the combined company’s product development
activities; the potential attributes and benefits of Quantum-Si’s
and the combined company’s products and services; Quantum-Si’s and
the combined company’s ability to obtain and maintain regulatory
approval for their products, and any related restrictions and
limitations of any approved product; Quantum-Si’s and the combined
company’s ability to identify, in-license or acquire additional
technology; Quantum-Si’s and the combined company’s ability to
maintain Quantum-Si’s existing license, manufacture and supply
agreements; Quantum-Si’s and the combined company’s ability to
compete with other companies currently marketing or engaged in the
development of products and services that Quantum-Si is developing;
the size and growth potential of the markets for Quantum-Si’s and
the combined company’s future products and services, and each of
their ability to serve those markets, either alone or in
partnership with others; the pricing of Quantum-Si’s and the
combined company’s products and services following anticipated
commercial launch; Quantum-Si’s and the combined company’s
estimates regarding future expenses, future revenue, capital
requirements and needs for additional financing; Quantum-Si’s and
the combined company’s financial performance; and other risks and
uncertainties indicated from time to time in HighCape’s Annual
Report on Form 10-K for the year ended December 31, 2020 and the
proxy statement/prospectus relating to the Business Combination,
including those under “Risk Factors” therein, and in HighCape’s
other filings with the SEC. HighCape and Quantum-Si caution that
the foregoing list of factors is not exclusive. HighCape and
Quantum-Si caution readers not to place undue reliance upon any
forward-looking statements, which speak only as of the date made.
HighCape and Quantum-Si do not undertake or accept any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based.
No Offer or Solicitation
This press release shall not constitute a solicitation of a
proxy, consent or authorization with respect to any securities or
in respect of the Business Combination. This press release shall
also not constitute an offer to sell or the solicitation of an
offer to buy any securities, nor shall there be any sale of
securities in any states or jurisdictions in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction.
No offering of securities shall be made except by means of a
prospectus meeting the requirements of section 10 of the Securities
Act of 1933, as amended, or an exemption therefrom.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210429005310/en/
Investor Relations Mike Cavanaugh or Mark Klausner
Westwicke, an ICR Company (646) 677-1838 QSI-IR@westwicke.com
Media Relations Cammy Duong Westwicke, an ICR Company
(203) 682-8380 QSI-PR@westwicke.com
HighCape Capital Acquisi... (NASDAQ:CAPA)
Historical Stock Chart
From Jan 2025 to Feb 2025
HighCape Capital Acquisi... (NASDAQ:CAPA)
Historical Stock Chart
From Feb 2024 to Feb 2025
